EyeYon Medical’s core products include the EndoArt® which is an artificial endothelial implant that can replace the human donor corneal endothelial and the Hyper CL which is a therapeutic contact lens for treating corneal edema, with drug delivery feature.

BELKIN Laser presents a unique non-contact automatic one-second SLT device, aimed at treating all different kinds of glaucoma, including POAG and PACG, to become the first-line choice for glaucoma therapy for every patient, all over the world.

The company focuses on innovative technology in presbyopic glasses.

6 Over 6 Vision is developing a suite of smartphone based pure-software online solution such as refractor, lens meter, PD meter and visual acuity testing, aiming to provide more people with online precision optical services anywhere

EyeControl has developed a set of intuitive eye gestures assistive communication devices, for ICU patients, ALS patients and others with locked-in syndrome, allowing them to communicate with doctors, nurses and family members through an intelligent communication system controlled by their eyes movements

Eximore is innovative company of ophthalmic drug delivery platform. It's developed a non-invasive eye delivery platform based on unique materials, It also can control the drugs to be released slowly and persistently in ocular surface, greatly improve the drug effect time and solve the compliance problem of using the eye drops.

Based on eye-tracking, propriety active glasses and other technologies, the company has developed a series of automated software and hardware products for amblyopia and strabismus screening, diagnosis and rehabilitation training, which can highly improve the diagnostic accuracy and treatment success of amblyopia and strabismus in children

Pykus Therapeutics, Inc. was founded in 2016 to develop a novel hydrogel to replace the use of intraocular gas during retinal surgery to make retinal surgery less painful and more successful.

The company is developing a small molecule drug to block formation of Aβ oligomers, the origin of Aβ protein toxicity, and reduce its damage to nerve cell. First time through the optic nerve level, we can treat glaucoma ($4Bn market), dry AMD (over 200mm patients and currently no treatment options) and Alzheimer's disease (optional).